At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 28 enrolled
Drug / intervention
Sitagliptin +1 moredrug
Likely dose
Sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Sitagliptin on Glucagon Counterregulation and Incretin Hormones During Mild Hypoglycemia in Elderly Patients With Metformin-treated Type 2 Diabetes
In Brief
A Phase 4 clinical trial evaluating Sitagliptin and Placebo for Type 2 Diabetes. Completed, enrolled 28 participants across 1 site.
Detailed Summary
To evaluate the effect of DPP-4 inhibition on glucagon counter-regulatory mechanisms at moderate hypoglycemia in metformin-treated subjects with T2DM
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesSweden
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartApr 2015
Primary CompletionJun 2017
TodayJul 2026
First PostedOct 3, 2014
Enrollment StartApr 1, 2015
Primary CompletionJun 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 11.7 years ago
Interventions
Sitagliptindrug
Sitagliptin 100 mg daily
Placebodrug
Placebo one tablet daily